Danilo Tagle's Biography

Danilo Tagle, Director, Office of Special Initiatives, National Center for Advancing Translational Sciences at the NIH (NCATS)

Dan Tagle is Director of the Office of Special Initiatives at NCATS where he many coordinates efforts towards development of disruptive technologies in translational research. He obtained his Ph.D. in Molecular Biology and Genetics from Wayne State University School of Medicine. He was an NIH National Research Service Award postdoctoral fellow in Human Genetics at the University of Michigan. He has served on numerous committees, advisory boards, and editorial boards. He has authored many scientific publications and has garnered numerous awards, including more recently the Roscoe O. Brady Award for Innovation and Accomplishment, and the Henry J. Heimlich Award for Innovative Medicine.

Developing Novel Point of Care Diagnostics to Detect SARS-CoV-2

Monday, 21 March 2022 at 17:00

Add to Calendar ▼2022-03-21 17:00:002022-03-21 18:00:00Europe/LondonDeveloping Novel Point of Care Diagnostics to Detect SARS-CoV-2Rapid Diagnostic Testing 2022 - SARS-CoV-2 and Beyond in BostonBostonSELECTBIOenquiries@selectbiosciences.com

The National Institutes of Health (NIH) launched the Rapid Acceleration of Diagnostics (RADx) initiative to meet the needs for COVID-19 diagnostic and surveillance testing, and also to speed its innovation in the development, commercialization, and implementation of new technologies and approaches. The RADx Radical (RADx-rad) initiative is one component of the RADx program which focuses on the development of new, or non-traditional applications of existing approaches, to enhance their usability, accessibility, and/or accuracy for the detection of SARS-CoV-2. This presentation will elaborate on two RADx rad programs led by the National Center for Advancing Translational Sciences on 1) pivoting technologies being developed for the isolation of exosomes towards screening and detection for SARS-CoV-2 viral infection due to the similar physical and chemical properties between exosomes and SARS-CoV-2 virus; and 2) developing novel biosensing capabilities using electronic nose technologies to detect unique signatures of volatile organic compounds (VOCs) of those with COVID-19 (Screening for COVID-19 by Electronic-Nose Technology (SCENT)).

Add to Calendar ▼2022-03-21 00:00:002022-03-22 00:00:00Europe/LondonRapid Diagnostic Testing 2022 - SARS-CoV-2 and BeyondRapid Diagnostic Testing 2022 - SARS-CoV-2 and Beyond in BostonBostonSELECTBIOenquiries@selectbiosciences.com

Conference Sponsors